Positives

• Retatrutide may be of interest to some Long COVID or ME/CFS patients because incretin drugs are being discussed around metabolic dysfunction, inflammation, appetite changes, and blood-sugar instability after illness, but I did not find strong retatrutide-specific Long COVID patient reports (Reddit).
• General patient reports describe highly variable response: some people feel appetite effects quickly, while others report little early effect and wait for dose changes, which matters for patients trying to interpret symptom changes carefully (Reddit).

Negatives

• Patient reports describe nausea, vomiting, diarrhea, food aversion, and sensitivity even at low doses, which could be especially difficult for Long COVID or ME/CFS patients with POTS, nausea, under-fueling, or medication sensitivity (Reddit).
• Fatigue is also a recurring patient concern, and one discussion includes a report of persistent heavy fatigue after only 1 mg, which is important for patients already disabled by fatigue or PEM (Reddit).

Hurdles & Side Effects

• Retatrutide is still investigational and is not an approved Long COVID or ME/CFS treatment; clinical data are mostly diabetes/obesity-focused and list nausea, diarrhea, vomiting, and dysesthesia among adverse events (Eli Lilly).
• Because it is not commercially approved, patients sourcing “research use” retatrutide face counterfeit, wrong-dose, contamination, and no-oversight risks (The Atlantic).